Brief: Pharnext To Announce Results From Phase 3 Trial Of Pxt3003 By October 2018
22/06/2018 06:59
June 22 (Reuters) - PHARNEXT SA PHARN.PA :
* ANNOUNCED ON THURSDAY UPDATE FROM PHASE 3 CLINICAL PROGRAM
EVALUATING PXT3003 FOR TREATMENT OF CHARCOT-MARIE-TOOTH TYPE 1A
DISEASE
* TOP-LINE RESULTS FROM PIVOTAL PLEO-CMT STUDY ARE NOW
EXPECTED BY
OCTOBER 2018
Source text for Eikon: urn:newsml:reuters.com:*:nBw9rH9r9a
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development